Y
Yvan Chanthery
Researcher at University of California, San Francisco
Publications - 14
Citations - 2703
Yvan Chanthery is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Neuroblastoma & Angiogenesis. The author has an hindex of 10, co-authored 12 publications receiving 2543 citations. Previous affiliations of Yvan Chanthery include Genentech & Santa Clara University.
Papers
More filters
Journal ArticleDOI
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis
John B. Ridgway,Gu Zhang,Yan Wu,Scott Stawicki,Wei-Ching Liang,Yvan Chanthery,Joe Kowalski,Ryan J. Watts,Christopher A. Callahan,Ian Kasman,Mallika Singh,May Chien,Christine Tan,Jo Anne Hongo,Fred de Sauvage,Greg Plowman,Minhong Yan +16 more
TL;DR: It is shown that Dll4-mediated Notch signalling has a unique role in regulating endothelial cell proliferation and differentiation, and is crucial during active vascularization, but less important for normal vessel maintenance.
Journal ArticleDOI
Blocking Neuropilin-1 Function Has an Additive Effect with Anti-VEGF to Inhibit Tumor Growth
Qi Pan,Yvan Chanthery,Wei-Ching Liang,Scott Stawicki,Judy Mak,Nisha Rathore,Raymond K. Tong,Joe Kowalski,Sharon Yee,Glenn Pacheco,Sarajane Ross,Zhiyong Cheng,Jennifer Le Couter,Greg Plowman,Franklin Peale,Alexander W. Koch,Yan Wu,Anil Bagri,Marc Tessier-Lavigne,Ryan J. Watts +19 more
TL;DR: It is proposed that blocking NRP1 function inhibits vascular remodeling, rendering vessels more susceptible to anti-VEGF therapy, and generated two monoclonal antibodies that bind to the Sema- and VEGF-binding domains of N RP1.
Journal ArticleDOI
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition
Alexandre Puissant,Stacey M. Frumm,Gabriela Alexe,Christopher F. Bassil,Jun Qi,Yvan Chanthery,Erin A. Nekritz,Rhamy Zeid,William Clay Gustafson,Patricia Greninger,Matthew J. Garnett,Ultan McDermott,Cyril H. Benes,Andrew L. Kung,William A. Weiss,James E. Bradner,Kimberly Stegmaier +16 more
TL;DR: A cell-based screen of genetically defined cancer cell lines using a prototypical inhibitor of BET bromodomains revealed a robust correlation between MYCN amplification and sensitivity to bromidomain inhibition, and characterized the mechanistic and translational significance of this finding in neuroblastoma.
Journal ArticleDOI
miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma
Alexander Swarbrick,Alexander Swarbrick,Susan L. Woods,Susan L. Woods,Alex D. Shaw,Alex D. Shaw,Alex D. Shaw,Asha Balakrishnan,Yuwei Phua,Yuwei Phua,Akira Nguyen,Yvan Chanthery,Lionel Lim,Lesley J. Ashton,Robert L. Judson,Noelle E. Huskey,Robert Blelloch,Michelle Haber,Murray D. Norris,Peter Lengyel,Christopher S. Hackett,Thomas Preiss,Thomas Preiss,Albert Chetcuti,Christopher S. Sullivan,Eric G. Marcusson,William A. Weiss,Noelle D. L'Etoile,Andrei Goga +28 more
TL;DR: A new mechanism of p53 regulation in cancer and stem cells is demonstrated and a potential therapeutic target for neuroblastoma is uncovered.
Journal ArticleDOI
Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library.
Wei-Ching Liang,Mark S. Dennis,Scott Stawicki,Yvan Chanthery,Qi Pan,Yongmei Chen,Charles Eigenbrot,Jianping Yin,Alexander W. Koch,Xiumin Wu,Napoleone Ferrara,Anil Bagri,Marc Tessier-Lavigne,Ryan J. Watts,Yan Wu +14 more
TL;DR: Panel of antibodies that cross-react with human and murine NRP1 were generated from a designed antibody phage library using a single human framework with a template containing human consensus complementarity-determining regions (CDRs) to investigate the possibility of function blocking antibodies to N RP1 as potential therapeutics.